{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:45:10Z","timestamp":1773294310100,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00120-026-02798-4","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:11:09Z","timestamp":1772626269000},"page":"324-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie des metastasierten hormonsensitiven Prostatakarzinoms","Treatment of metastatic hormone-sensitive prostate cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"Marc-Oliver","family":"Grimm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Hatem","family":"Albarghouth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2798_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2025) S3-Leitlinie Prostatakarzinom, Langversion 8.1, 2025, AWMF-Registernummer: 043-022OL. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/2025-08-22_LL_Prostatakarzinom_Langversion_8.1.pdf. Accessed 20.11.2025"},{"issue":"15","key":"2798_CR2","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong\u00a0AJ et\u00a0al (2022) Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J\u00a0Clin Oncol 40(15):1616\u20131622","journal-title":"J Clin Oncol"},{"issue":"2","key":"2798_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","volume":"8","author":"W Fukuokaya","year":"2025","unstructured":"Fukuokaya\u00a0W et\u00a0al (2025) Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. Eur Urol Oncol 8(2):263\u2013269","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"2798_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1200\/JCO.23.01535","volume":"42","author":"S Halabi","year":"2024","unstructured":"Halabi\u00a0S et\u00a0al (2024) Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. J\u00a0Clin Oncol 42(9):1044\u20131054","journal-title":"J Clin Oncol"},{"issue":"5","key":"2798_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11523-018-0588-8","volume":"13","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli\u00a0R et\u00a0al (2018) Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. Target Oncol 13(5):649\u2013655","journal-title":"Target Oncol"},{"issue":"4","key":"2798_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi\u00a0K et\u00a0al (2017) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"8","key":"2798_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney\u00a0CJ et\u00a0al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"5","key":"2798_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard\u00a0CC et\u00a0al (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375(5):443\u201353","journal-title":"N Engl J Med"},{"issue":"5","key":"2798_CR9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/JU.0000000000003186","volume":"209","author":"KE Breen","year":"2023","unstructured":"Breen\u00a0KE et\u00a0al (2023) Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. J\u00a0Urol 209(5):918\u2013927","journal-title":"J Urol"},{"issue":"14","key":"2798_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro\u00a0E et\u00a0al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J\u00a0Clin Oncol 31(14):1748\u20131757","journal-title":"J Clin Oncol"},{"issue":"32","key":"2798_CR11","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong\u00a0AJ et\u00a0al (2019) ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J\u00a0Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"issue":"1","key":"2798_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi\u00a0KN et\u00a0al (2019) Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 381(1):13\u201324","journal-title":"N Engl J Med"},{"issue":"20","key":"2798_CR13","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain\u00a0M et\u00a0al (2023) Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J\u00a0Clin Oncol 41(20):3595\u20133607","journal-title":"J Clin Oncol"},{"issue":"36","key":"2798_CR14","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad\u00a0F et\u00a0al (2024) Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J\u00a0Clin Oncol 42(36):4271\u20134281","journal-title":"J Clin Oncol"},{"issue":"4","key":"2798_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James\u00a0ND et\u00a0al (2017) Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 377(4):338\u2013351","journal-title":"N Engl J Med"},{"issue":"5","key":"2798_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi\u00a0K et\u00a0al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"issue":"11","key":"2798_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","volume":"20","author":"N Agarwal","year":"2019","unstructured":"Agarwal\u00a0N et\u00a0al (2019) Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol 20(11):1518\u20131530","journal-title":"Lancet Oncol"},{"issue":"20","key":"2798_CR18","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi\u00a0KN et\u00a0al (2021) Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J\u00a0Clin Oncol 39(20):2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"12","key":"2798_CR19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith\u00a0MR et\u00a0al (2022) Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386(12):1132\u20131142","journal-title":"N Engl J Med"},{"issue":"12","key":"2798_CR20","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke\u00a0NW et\u00a0al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992\u20132003","journal-title":"Ann Oncol"},{"issue":"10024","key":"2798_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James\u00a0ND et\u00a0al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163\u20131177","journal-title":"Lancet"},{"issue":"2","key":"2798_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis\u00a0G et\u00a0al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158","journal-title":"Lancet Oncol"},{"issue":"6","key":"2798_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","volume":"73","author":"G Gravis","year":"2018","unstructured":"Gravis\u00a0G et\u00a0al (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73(6):847\u2013855","journal-title":"Eur Urol"},{"key":"2798_CR24","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF-Registernummer: 043-022OL. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Prostatatkarzinom\/Version_6\/LL_Prostatakarzinom_Langversion_6.2.pdf. Accessed 24.11.2025"},{"key":"2798_CR25","unstructured":"European Medicines Agency. Fachinformation Docetaxel. [cited 2025 09.05.]; Available from: https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/taxotere-epar-product-information_de.pdf."},{"key":"2798_CR26","unstructured":"European Medicines Agency. Fachinformation Darolutamid. [cited 2025 03.04.]; Available from: www.ema.europa.eu\/de\/documents\/product-information\/nubeqa-epar-product-information_de.pdf."},{"key":"2798_CR27","unstructured":"European Medicines Agency. Fachinformation Abirateron. [cited 2025 03.04.]; Available from: www.ema.europa.eu\/de\/documents\/product-information\/zytiga-epar-product-information_de.pdf."},{"key":"2798_CR28","unstructured":"European Medicines Agency. Fachinformation Apalutamid. [cited 2025 03.04.]; Available from: www.ema.europa.eu\/de\/documents\/product-information\/erleada-epar-product-information_de.pdf."},{"key":"2798_CR29","unstructured":"European Medicines Agency. Fachinformation Enzalutamid. [cited 2025 03.04.]; Available from: www.ema.europa.eu\/de\/documents\/product-information\/xtandi-epar-product-information_de.pdf."},{"issue":"2","key":"2798_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","unstructured":"Kellokumpu-Lehtinen\u00a0PL et\u00a0al (2013) 2\u2011Weekly versus 3\u2011weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14(2):117\u2013124","journal-title":"Lancet Oncol"},{"key":"2798_CR31","doi-asserted-by":"crossref","unstructured":"Grimm MO et\u00a0al (2025) 3\u2011Weekly Docetaxel 75\u202fmg\/m2 vs 2\u2011Weekly Docetaxel 50\u202fmg\/m2 in Combination with Darolutamide + ADT in Patients with mHSPC \u2013 Results from the Randomised Phase\u00a03 ARASAFE Trial, in ESMO Annual Congress 2025.","DOI":"10.1016\/j.annonc.2025.09.108"},{"key":"2798_CR32","doi-asserted-by":"crossref","unstructured":"Attard, G., et\u00a0al., Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a\u00a0randomized phase\u00a03\u00a0trial. Nat Med, 2025.","DOI":"10.1038\/s41591-025-03961-8"},{"key":"2798_CR33","unstructured":"Standard of Care +\/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders). [cited 21.08.2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06496581."},{"key":"2798_CR34","unstructured":"Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH). [cited 21.08.2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06592924."},{"key":"2798_CR35","unstructured":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors. [cited 21.08.2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05974774."}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02798-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:50:39Z","timestamp":1773233439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02798-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02798-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"13 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Die Originalversion dieses Artikels wurde korrigiert: Im Literaturverzeichnis wurden Produktnamen entfernt.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"M.-O.\u00a0Grimm\n                      : A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: BMS, Intuitive Surgical, Bayer Vital (au\u00dferhalb der eingereichten Arbeit). \u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: AstraZeneca, BMS, Ipsen, MSD, Pfizer, Astellas, EUSA Pharma, Merck Serono, Bayer Vital, Janssen, Novartis (au\u00dferhalb der eingereichten Arbeit). \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u00a0\u00e4.: AstraZeneca, BMS, Ipsen, MSD, Pfizer, Astellas, EUSA Pharma, Merck Serono, Roche Pharma AG, Eisai, Bayer Vital, Janssen, Gilead, Novartis, Takeda (au\u00dferhalb der eingereichten Arbeit). \u2013 B. Nichtfinanzielle Interessen: Direktor der Klinik und Poliklinik f\u00fcr Urologie, Universit\u00e4tsklinikum Jena | Mitgliedschaften: DGU, EAU, ESOU.\n                      K.\u00a0Leucht\n                      : A. Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Ipsen (au\u00dferhalb der eingereichten Arbeit). \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u00a0\u00e4.: Janssen, Urotrials (au\u00dferhalb der eingereichten Arbeit). \u2013 B. Nichtfinanzielle Interessen: Angestellt als wissenschaftliche Mitarbeiterin am Universit\u00e4tsklinikum Jena.\n                      M.\u00a0Marx\n                      : A. Finanzielle Interessen: M. Marx gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Assistenzarzt der Klinik und Poliklinik f\u00fcr Urologie des Universit\u00e4tsklinikums Jena.\n                      M.\u00a0Sperling\n                      : A. Finanzielle Interessen: M. Sperling gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Assistenzarzt der Klinik und Poliklinik f\u00fcr Urologie des Universit\u00e4tsklinikums Jena.\n                      M.\u00a0H.\u00a0Albarghouth\n                      : A. Finanzielle Interessen: M. H. Albarghouth gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Oberarzt, Universit\u00e4tsklinikum Jena.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}